Market Size (2017)
2017
$28.14B
Vertical: HealthcareBase Year: 201911 Sections
Market Size (2017)
2017
$28.14B
Projected (2027)
2027
$64.27B
CAGR (2017–2027)
8.6%
8.6%Key Players
110+
With an increasing incidence rate of chronic and life-threatening diseases, the demand for precise diagnostic procedures is increasing. In addition to that, there is an increase in the number of manufacturers, distributors, and service providers of biomarkers across the globe, creating enormous growth opportunities in the market.
Market Attractiveness Analysis
Global Biomarkers Market, by Product
Global Biomarkers Market, by Type
Global Biomarkers Market, by Application
Global Biomarkers Market, by Disease Indication
The Biomarkers Market market is projected to grow at a CAGR of 8.6% from 2017 to 2027.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansA biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a physiological as well as a pathological process or pharmacological response to a therapeutic intervention.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans1 Research Methodology
The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistic agencies, and paid databases. This information creates a base for the study. This information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points that currently affect or are likely to affect the industry over the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation & forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for over the forecast period.
After estimating the market sizes & estimates, numbers are verified with the industry participants and key opinion leaders. The wide network of industry participants performs a value addition in the research and verify the numbers & estimates of the study. In the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The figure below contains the different stages of the whole research performed to produce the report.
1.1 DATA MINING
Data mining is one of the extensive stages of our research process. It involves the procurement of market data and related information through different verified & credible sources. This step helps to obtain the raw information about the supply chain of the industry, the monetary process of different end-uses, the pool of market participants & the nature of the industry, and the scope of the study. The data mining stage comprises both primary as well as secondary sources of information.
1.2 SECONDARY RESEARCH
In the process of secondary research, various sources are referred to identify and collect industry trends and information for the research process. We at MRFR have access to some of the most diversified and extensive paid databases which give us the most accurate data/information on market sizes, components, and pricing. Below mentioned is the detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned, we also deploy dynamic access to different other data sources depending on the need for research.
Market Sizing & Revenue
Qualitative Information & Trends
Company Websites
· White Papers
· Magazines
· Company Websites
· Annual Reports
· Press Releases
· Investor Presentations
· Paid Databases
· Authenticated Directories
· Independent Studies
· US Department of Health and Human Services
· Centers for Disease Control and Prevention
· Organization for Economic Co-operation and Development
· Agency for Healthcare Research and Quality
· World Health Organization (WHO)
· National Health Service (NHS)
· American Heart Association
· Emergency Care Research Institute (ECRI)
· Cancer Research UK
· National Center for Biotechnology Information (NCBI)
· European Society for Medical Oncology
· Annals of Clinical and Translational Neurology
· World Cancer Research Fund International
· National Cancer Institute
· International Agency for Research on Cancer
· Cancer Council
· European Society of Cardiology
· Cardiac Society of Australia & New Zealand
· The Chinese Society for Immunology
· Others
Annual Reports
Investor Presentations
Authenticated Directories
Hoover’s, Factiva, Bloomberg
1.3 PRIMARY RESEARCH
In the primary research process for data mining to analyze the market share of each key player, in-depth primary interviews are conducted with the CXO’s to understand their market share, customer base, pricing strategy, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXO’s of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both supply and demand-side are interviewed to obtain both qualitative as well as quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies are conducted to obtain critical qualitative and quantitative aspects pertaining to the market, as well as to assess the prospects for market growth over the forecast period. The detailed information of these primary respondents is mentioned below in the table:
Primary Source
Product Side Subject Matter Experts, Top Management, and CXOs
Technical Persons of Organizations Operating in the Market
Marketing and Business Development Managers, VPs, and Marketing Directors
Various Partner Consultants from the Demand and Supply Sides
TABLE 1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
Respondents
Data Points Received
Product Manufacturers/Distributors/Service Providers
· Market Size
· Top of the Mind Key Market Players
· Direct Competitors
· Company Market Shares
· Growth Rate (%)
· Market Trends and Prominent Market Drivers
· Major Brands
· Product Pricing and Catalogues
· Service Cost
· Demand and Supply Scenario
· Types of Services
· Regional Scenario
· Market Trends
End Users
· Adoption of New Technologies
· Acceptance Ratio
· Product Cost
· Service Cost
· Top Products & Services
· Usage and Applications
· Procedure Price
1.1 FORECASTING TECHNIQUES
We at MRFR follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques, as mentioned below.
Forecasting Techniques
Description
Qualitative and Quantitative Analysis
A combination of qualitative approach, i.e., primary interviews with industry experts to understand the interviewees’ opinions and judgments, more commonly known as the Delphi method, and quantitative analysis to forecast future data based on historical and current data.
Weighted Average Approach
Via this approach, future data is calculated based on the mean of the past data under the assumption that some factors affecting the market in the past will continue to have a similar impact in the future.
Drift Method
This approach is used to vary the forecast, that is, increase or decrease market factor over time depending on various parameters affecting the change in the trends of the market.
Time Series Methods
The integration of several time series methods such as moving average, moving weighted average, linear prediction, and trend estimation is applied while determining the year-on-year growth rate and the compound annual growth rate of the market being studied.
Causal/Econometric Forecasting Methods
Various economic factors such as inflation rate, fiscal policies, changes in government regulations, taxes, labor costs, and interest rates are taken into consideration while determining the current market size and predicting the future market growth rate.
Judgmental Methods
This involves a collection of intuitive judgment, opinions, and probability estimates from industry experts in the case of new or upcoming markets/technologies for which no prior data is available.
Regression Analysis
This type of statistical modeling is carried out for predicting and forecasting dependent and independent variables that will directly or indirectly impact the market.
Probabilistic Forecasting
This forecasting method is carried out to assign a probability to every possible outcome ranging from the least optimistic to highly optimistic, which helps in gauging the market under stable conditions.
PESTLE Analysis
Political, economic, social, technological, legal, and environmental factors are taken into consideration while deriving the fluctuations in the growth rate of the market.
Porter’s Five Forces Analysis
By understanding the supplier-side and demand-side factors, the current market scenario can be estimated, and future market scenarios predicted, which aid in deriving the growth rate of the market.
1.2 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
Understanding the market in terms of valuation is a crucial task. This becomes significantly important while investing in and choosing the correct business opportunities. In this regard, we at MRFR undertake two market sizing approaches simultaneously, namely, the top-down and bottom-up approaches. In this step, we assess different data points, numeric attributes, information, and industry trends to arrive at the estimates and forecast values for the coming years. We use different mathematical models to estimate the market sizes of different economies and segments, each of which is further summed up to define the total market.
We at MRFR employ a proprietary statistical tool for market estimations, which helps us to arrive at market size estimates and forecasts for different markets and industries.
1.1.1 BOTTOM-UP APPROACH
In the bottom-up approach, the revenue of key companies and their shares in the market are assessed to deduce the market size. More than 75% of the key players operating in the global biomarkers market are studied. The segmental revenue of each player is analyzed, and the size for the global biomarkers market is extracted from the segmental/product revenue with the help of secondary and primary research. The extracted size for the market is then validated with industry experts and partner consultants. This derived market size contributes to around 75% to 80% of the total market share in terms of revenue for the global biomarkers market. Using the data triangulation method, the overall market size is estimated.
1.1.2 TOP-DOWN APPROACH
The overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research.
The countries considered in the scope of the global biomarkers market are the US, Canada, Brazil, Argentina, Mexico, Colombia, Chile, Peru, Uruguay, Venezuela, Russia, Poland, the UK, Germany, France, Italy, Spain, Switzerland, Austria, Belgium, Denmark, Finland, Greece, Hungary, Czech Republic, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Slovakia, Sweden, Romania, Ireland, China, Japan, Malaysia, Indonesia, Thailand, Vietnam, the Philippines, South Korea, Pakistan, Singapore, India, Australia & New Zealand, South Africa, Egypt, Nigeria, Saudi Arabia, Qatar, the UAE, Bahrain, Kuwait, Oman, Turkey, and others. However, the availability of the products and services can differ owing to the product clearance and approval processes.
The figure below depicts the process of market estimation using independent tools employed by our analysts to arrive at the sizing of the market.
DATA TRIANGULATION
After arriving at the overall market sizes, the total market is divided into several segments and sub-segments. Again, the market breakdown and data triangulation procedures are implemented, wherever applicable, to complete the overall market engineering process and gather the exact statistics for all segments and sub-segments. The data is triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size is validated using the top-down and bottom-up approaches.
VALIDATION
Validation is the most important stage of the report making the process. Validation via an intricately designed feedback process helps us finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic and personal interviews, e-mails, feedback forms, questionnaires, and polling options/answers with a group of relevant industry participants. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models, and conclusions.
Base Year
2019
Historical Period
2017 – 2019
Forecast Period
2019 – 2027
Primary Interviews
150+
Historical data (2017–2019) and forecast period (2019–2027)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
There is a huge number of suppliers in the market. The bargaining power of suppliers in this market is medium to high. Suppliers in this market mainly comprise manufacturers & service providers of biomarkers assay and kits. In developing regions such as Asia-Pacific, the suppliers are providing their products at competitive prices. Major market players have large R&D budgets and are fully capable of producing each component in-house, which creates a competitive edge on the pricing. Also, another factor that affects the bargaining power of suppliers is the number of raw material suppliers. Therefore, the bargaining power of suppliers in this market is medium to high.
Bargaining Power of Buyers
The bargaining power of buyers is medium to high in the global biomarkers market. The major buyers for the market are hospitals & clinics and diagnostic centers. There is a large number of buyers in the market. The buyers of biomarkers across the globe are highly inclined towards brand identity to ensure the best quality products to the customers. Moreover, the buyers can exert moderate pressure on the biomarkers manufacturing companies as some of the companies sell their products at a very high cost due to the use of advanced technology. There are many companies providing good quality products due to which the bargaining power of the buyers is medium to high.
Threat of New Entrants
The threat of new entrants is medium in the biomarkers market. Any pharmaceutical/medical device company trying to enter the market must face numerous barriers, such as band loyalty, switching cost, capital investment, government regulations, and patents. Well-known brands hold an advantage in the market, as recognition is linked to the quality of the product. Moreover, it is a very high-tech industry, with a large amount of investment required for research & development costs, and the market is very strongly regulated, varying from country to country. Suppliers must comply with international standards to remain competitive. Thus, the above factors affect the entry of new players moderately.
Threat of Substitutes
The threat of substitutes in the global biomarkers market is low. The buyer’s inclination to substitute is low to moderate due to the smaller number of alternative products available in the market. Factors such as reimbursement cuts, and high competition, may propel biomarkers manufacturers to provide technologically advanced systems at low costs for mature markets in the coming years. Thus, these factors affect the threat of substitutes.
Intensity of Rivalry
The degree of competition in the biomarkers market is moderate to high. The modest degree of product differentiation among existing players increases the intensity of rivalry in the market. Biomarkers manufacturing companies are trying to develop less expensive products to make more affordable products in developing regions. In addition, brand loyalty moderately affects the market as buyers are inclined towards established MNCs. To overcome the competition, players are engaged in developing their processes to lower their manufacturing costs.
Market estimates by geography (2027)
InsightAmericas leads with $23.62B by 2027, while Asia Pacific is projected to grow fastest at a 9.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2017 | 2019 | 2027 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $5.66B | $8.07B | $14.00B | 9.5% | 22% |
| Americas | $11.11B | $14.69B | $23.62B | 7.8% | 37% |
| Europe | $9.70B | $13.51B | $22.88B | 9.0% | 36% |
| Middle East and Africa | $1.66B | $2.28B | $3.77B | 8.5% | 6% |
| Total | $28.14B | $38.56B | $64.27B | 8.6% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$64.27B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Product_Consumables | $32.42B | 8.6% | 47% |
| Product_Services | $24.26B | 8.6% | 54% |
| Product_Software | $7.58B | 8.6% | 54% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Biomarkers Market covering market dynamics, competitive landscape, and strategic outlook.
The Biomarkers Market market is projected to reach $64.27B by 2027, growing at 8.6% CAGR. The Product_Consumables segment holds the largest share.
Biomarkers are biological markers that help to indicate normal or abnormal development taking place in the human body and help to direct certain diseases. Various types of molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers, as they all give health updates.
The global biomarkers market is driven by increasing applications of biomarkers, R&D funding by pharmaceutical and biotechnology companies, rising prevalence of cancer, and other chronic diseases, and new initiatives for biomarker research. Additionally, the rapidly growing population worldwide and increasing product launches by major players are likely to enhance the growth of the global biomarkers market.
Biomarkers are capable of detecting or confirming the presence of a disease or identifying different diseases, sub-types, and even different habitats within a single lesion. They also help understand why a tumor is responding to treatment, while other identical tumors are not, and to measure susceptibility to develop a disease potentially. The use of biomarkers generates a huge amount of genomic or transcriptomic data. Extracting the key biomarkers associated with clinical response to a specific therapy needs a tremendous combination of scientific expertise, and a panel of bioinformatics and biostatistics tools, in which artificial intelligence play one of the success factors.
Artificial intelligence (AI) can automate a large portion of the manual work and speed up the process. The algorithms classify molecules into good and bad candidates and help clinicians focus on analyzing the best prospects. Hence, the incorporation of AI in biomarker validation will act as a driving factor in the near future.
Validation of biomarkers is a lengthy process due to its time-consuming and expensive nature. Validation of biomarkers along with FDA approval requires at least 15 years, and the expense exceeds over USD 1 billion. Huge capital investments are required for the discovery, development, and validation of biomarkers. This hampers the growth of the biomarkers market and other related markets such as diagnostics and personalized medicines.
Additionally, due to high drug attrition rate in clinical trials (with almost 30% of drugs failing in phase III), diagnostics manufacturers face enormous financial challenges. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations in 2015, 56 new pharmaceuticals were launched, out of more than 7,000 compounds that were in development. Manufacturers need successful phase III clinical trials, which is dependent on well-validated biomarker tests. Huge investments are required to run clinical trials. This affects small companies to develop biomarkers but also severely affects innovation. Hence, along with high capital investments, the low cost-benefit ratio also hinders the market growth.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 110 companies operating in the Biomarkers Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
Signosis
Company Headquarters: California, US Founded: 2007 Company Working: Signosis is a molecular tool company that is focused on developing innovative and unique products for biomarker discovery and analysis in the areas of life science research, clinical application, and drug discovery. The company offers a wide selection of validated luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways in many cell lines and provide a wide spectrum of over-expression stable cell lines, including a series of EGFR mutant over-expression stable cell lines. In addition to that, Signosis provides custom services in making custom assay kits and performing the assay and data analysis, generating custom stable cell lines to facilitate scientists’ research projects. It has distributors all around the world, including Germany, the UK, France, Sweden, Norway, Denmark, Finland, Italy, Australia, Egypt, Israel, Korea, Japan, Taiwan, and China.
Enzo Biochem Inc.
Company Headquarters: New York, US Founded: 1976 Workforce: ~460 Company Working: Enzo Biochem Inc. is a life science, and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics, and therapeutics and provides reference laboratory services to the medical community. The company has significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials. It operates three wholly-owned subsidiaries, namely, Enzo Life Sciences, Enzo Therapeutics, and Enzo Clinical Labs.
EKF Diagnostics
Company Headquarters: Penarth, Cardiff, UK Founded: 1990 Workforce: ~300 Company Working: EKF Diagnostics is a healthcare company. It specializes in the development, manufacture, and distribution of point of care analyzers for hemoglobin, HbA1c, glucose, lactate, as well as a wide range of clinical chemistry products and biomarker-based ELISA and rapid tests. EKF Diagnostics provides its products to more than 100 countries. It is listed on the alternative investment market at the London Stock Exchange
Qiagen
Company Headquarters: Germany, Europe Founded: 1984 Workforce: 5,000 Company Working: Qiagen is a healthcare company that deals in sample and assay technologies for molecular diagnostics. The company operates through more than 35 offices spread in over 25 countries. It serves more than 500,000 customers across the globe. Its product portfolio spans through a full range of molecular testing applications. Qiagen’s products are used for extraction, purification, and stabilization of DNA, RNA, and protein from various biological samples. It has over 500 core products in its portfolio. The company is listed on the New York Stock and Frankfurt Prime Standard exchanges. It offers its products in various areas such as discovery & translational research, diagnostics & clinical research, next-generation sequencing, and instruments & automation.
Merck KGaA
Company Headquarters: Darmstadt, Germany Founded: 1668 Workforce: ~60,348 Company Working: Merck KGaA (Merck) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and is dedicated to providing breakthrough solutions and technologies. The company research drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. It also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for industries such as pharmaceuticals, food, cosmetics, packaging, and coatings. It has expanded its global footprint through several mergers and acquisitions, such as the acquisition of Millipore and Sigma-Aldrich. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, New Zealand among others.
F. HOFFMANN-LA ROCHE LTD
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Biomarkers Market